Worldwide, thousands of male patients who carry ATP Binding Cassette Subfamily D Member 1 (ABCD1) mutations develop adrenomyeloneuropathy (AMN) in mid-adulthood, a debilitating axonopathy of the spinal cord. Today AAV gene therapy brings the most hope for this orphan disease. We previously reported that an AAV9-MAG-hABCD1 vector injected intravenously in the neonatal period prevented the disease in 2-year-old Abcd1−/− mice, the AMN mouse model. In the current study, the same vector was injected intracisternally at 18 months of age, when about half of Abcd1−/− mice start losing balance and motricity. As soon as 1–3 months after vector injection, motor tests have evolved differently in treated and untreated (UT) mice. Six months after vector, treated mice (n = 24) had near-normal motor performances, whereas neurological state had deteriorated in UT mice (n = 34). In five white matter regions of the cervical spinal cord, hABCD1 expression at 24 months of age was present in 22% (18–27) of oligodendrocytes (OLs) and 22% (17–26) of astrocytes and not detected in neurons or microglia. Abundant hABCD1 expression was also observed in OLs and astrocytes in the cerebellum and brainstem and, to a lesser level, in the lower spinal cord, not in the dorsal root ganglia or brain cortex. In conclusion, the effect of the AAV9-MAG-hABCD1 vector at an early symptomatic stage of the Abcd1−/− mouse model paves a new oligotropic way for the gene therapy of AMN.
Get full access to this article
View all access options for this article.
References
1.
Özgür-GünesY, ChedikM, Le StunffC, et al.Long-Term disease prevention with a gene therapy targeting oligodendrocytes in a mouse model of adrenomyeloneuropathy. Hum Gene Ther, 2022; 33(17–18):936–949; doi: 10.1089/hum.2021.293
2.
WeinhoferI, RommerP, GleissA, et al.Biomarker-based risk prediction for the onset of neuroinflammation in X-linked adrenoleukodystrophy. EBioMedicine, 2023; 96:104781; doi: 10.1016/j.ebiom.2023.104781
3.
PowersJM, DeCieroDP, ItoM, et al.Adrenomyeloneuropathy: A neuropathologic review featuring its noninflammatory myelopathy. J Neuropathol Exp Neurol, 2000; 59(2):89–102; doi: 10.1093/jnen/59.2.89
4.
CastellanoA, PapinuttoN, CadioliM, et al.Quantitative MRI of the spinal cord and brain in adrenomyeloneuropathy: In vivo assessment of structural changes. Brain, 2016; 139(Pt 6):1735–1746; doi: 10.1093/brain/aww068
5.
FatemiA, SmithSA, DubeyP, et al.Magnetization transfer MRI demonstrates spinal cord abnormalities in adrenomyeloneuropathy. Neurology, 2005; 64(10):1739–1745; doi: 10.1212/01.Wnl.0000164458.02141.06
6.
SengulG, WatsonC, TanakaI, et al.Atlas of the Spinal Cord of the Rat, Mouse, Marmoset, Rhesus and Human. Academic Press Inc; 2012.
7.
LiangH, PaxinosG, WatsonC. Projections from the brain to the spinal cord in the mouse. Brain Struct Funct, 2011; 215(3–4):159–186; doi: 10.1007/s00429-010-0281-x
8.
PowersJM, DeCieroDP, CoxC, et al.The dorsal root ganglia in adrenomyeloneuropathy: Neuronal atrophy and abnormal mitochondria. J Neuropathol Exp Neurol, 2001; 60(5):493–501; doi: 10.1093/jnen/60.5.493
9.
PujolA, HindelangC, CallizotN, et al.Late onset neurological phenotype of the X-ALD gene inactivation in mice: A mouse model for adrenomyeloneuropathy. Hum Mol Genet, 2002; 11(5):499–505; doi: 10.1093/hmg/11.5.499
WatsonC, HarrisonM. The location of the major ascending and descending spinal cord tracts in all spinal cord segments in the mouse: Actual and extrapolated. Anat Rec (Hoboken), 2012; 295(10):1692–1697; doi: 10.1002/ar.22549
12.
LaunayN, Lopez-ErauskinJ, BianchiP, et al.Imbalanced mitochondrial dynamics contributes to the pathogenesis of X-linked adrenoleukodystrophy. Brain, 2024; 147(6):2069–2084; doi: 10.1093/brain/awae038
13.
SchlüterA, EspinosaL, FourcadeS, et al.Functional genomic analysis unravels a metabolic-inflammatory interplay in adrenoleukodystrophy. Hum Mol Genet, 2012; 21(5):1062–1077; doi: 10.1093/hmg/ddr536
14.
StrachanLR, StevensonTJ, FreshnerB, et al.A zebrafish model of X-linked adrenoleukodystrophy recapitulates key disease features and demonstrates a developmental requirement for abcd1 in oligodendrocyte patterning and myelination. Hum Mol Genet, 2017; 26(18):3600–3614; doi: 10.1093/hmg/ddx249
15.
FouquetF, ZhouJM, RalstonE, et al.Expression of the adrenoleukodystrophy protein in the human and mouse central nervous system. Neurobiol Dis, 1997; 3(4):271–285; doi: 10.1006/nbdi.1997.0127
16.
GongY, LahejiF, BerensonA, et al.Role of basal forebrain neurons in adrenomyeloneuropathy in mice and humans. Ann Neurol, 2024; 95(3):442–458; doi: 10.1002/ana.26849
17.
HöftbergerR, KunzeM, WeinhoferI, et al.Distribution and cellular localization of adrenoleukodystrophy protein in human tissues: Implications for X-linked adrenoleukodystrophy. Neurobiol Dis, 2007; 28(2):165–174; doi: 10.1016/j.nbd.2007.07.007
18.
BenhamidaS, FouquetF, MoserA, et al.Phenotypic correction of ALD mouse after hematopoietic cell transplantation and evaluation of hematopoietic stem cell gene therapy with a lentivirus vector. 2004.
19.
GongY, BerensonA, LahejiF, et al.Intrathecal adeno-associated viral vector-mediated gene delivery for adrenomyeloneuropathy. Hum Gene Ther, 2019; 30(5):544–555; doi: 10.1089/hum.2018.079
20.
NaveKA, AsadollahiE, SasmitaA. Expanding the function of oligodendrocytes to brain energy metabolism. Curr Opin Neurobiol, 2023; 83:102782; doi: 10.1016/j.conb.2023.102782
21.
ChamberlainKA, ShengZH. Mechanisms for the maintenance and regulation of axonal energy supply. J Neurosci Res, 2019; 97(8):897–913; doi: 10.1002/jnr.24411
22.
KassmannCM. Myelin peroxisomes - essential organelles for the maintenance of white matter in the nervous system. Biochimie, 2014; 98:111–118; doi: 10.1016/j.biochi.2013.09.020
23.
ChrastR, SaherG, NaveKA, et al.Lipid metabolism in myelinating glial cells: Lessons from human inherited disorders and mouse models. J Lipid Res, 2011; 52(3):419–434; doi: 10.1194/jlr.R009761
24.
WandersRJ. Metabolic functions of peroxisomes in health and disease. Biochimie, 2014; 98:36–44; doi: 10.1016/j.biochi.2013.08.022
25.
von JonquieresG, FröhlichD, KlugmannCB, et al.Recombinant human myelin-associated glycoprotein promoter drives selective AAV-Mediated transgene expression in oligodendrocytes. Front Mol Neurosci, 2016; 9:13; doi: 10.3389/fnmol.2016.00013
26.
Özgür GünesY. Preclinical Gene Therapy using Recombinant AAV Vectors in Mouse Models of Two Human Diseases. Paris-Saclay University: 2022.
27.
PriestleyJRC, AdangLA, Drewes WilliamsS, et al.Newborn screening for X-Linked adrenoleukodystrophy: Review of data and outcomes in Pennsylvania. Int J Neonatal Screen, 2022; 8(2); doi: 10.3390/ijns8020024
28.
FlurkeyK, CurrerJM, HarrisonDE. The Mouse in Medical Research. Academic Press; 2007.
29.
MaCY, LiC, ZhouX, et al.Management of adrenoleukodystrophy: From pre-clinical studies to the development of new therapies. Biomed Pharmacother, 2021; 143:112214; doi: 10.1016/j.biopha.2021.112214
30.
ManorJ, ChungH, BhagwatPK, et al.ABCD1 and X-linked adrenoleukodystrophy: A disease with a markedly variable phenotype showing conserved neurobiology in animal models. J Neurosci Res, 2021; 99(12):3170–3181; doi: 10.1002/jnr.24953
31.
BaileyRM, ArmaoD, Nagabhushan KalburgiS, et al.Development of Intrathecal AAV9 Gene Therapy for Giant Axonal Neuropathy. Mol Ther Methods Clin Dev, 2018; 9:160–171; doi: 10.1016/j.omtm.2018.02.005
32.
BeyK, CironC, DubreilL, et al.Efficient CNS targeting in adult mice by intrathecal infusion of single-stranded AAV9-GFP for gene therapy of neurological disorders. Gene Ther, 2017; 24(5):325–332; doi: 10.1038/gt.2017.18
33.
KojicM, GaikM, KiskaB, et al.Elongator mutation in mice induces neurodegeneration and ataxia-like behavior. Nat Commun, 2018; 9(1):3195; doi: 10.1038/s41467-018-05765-6
34.
LuongTN, CarlisleHJ, SouthwellA, et al.Assessment of motor balance and coordination in mice using the balance beam. J Vis Exp, 2011; 49(49); doi: 10.3791/2376
35.
SchulzA, WaltherC, MorrisonH, et al.In vivo electrophysiological measurements on mouse sciatic nerves. J Vis Exp, 2014; 86(86); doi: 10.3791/51181
36.
DaciR, FlotteTR. Delivery of adeno-associated virus vectors to the central nervous system for correction of single gene disorders. Int J Mol Sci, 2024; 25(2); doi: 10.3390/ijms25021050
37.
TatsumiK, IsonishiA, YamasakiM, et al.Olig2-Lineage astrocytes: A distinct subtype of astrocytes that differs from GFAP astrocytes. Front Neuroanat, 2018; 12:8; doi: 10.3389/fnana.2018.00008
38.
OhayonD, AguirrebengoaM, EscalasN, et al.Transcriptome profiling of the Olig2-expressing astrocyte subtype reveals their unique molecular signature. iScience, 2021; 24(7):102806; doi: 10.1016/j.isci.2021.102806
39.
WangH, XuL, LaiC, et al.Region-specific distribution of Olig2-expressing astrocytes in adult mouse brain and spinal cord. Mol Brain, 2021; 14(1):36; doi: 10.1186/s13041-021-00747-0
40.
CahoyJD, EmeryB, KaushalA, et al.A transcriptome database for astrocytes, neurons, and oligodendrocytes: A new resource for understanding brain development and function. J Neurosci, 2008; 28(1):264–278; doi: 10.1523/jneurosci.4178-07.2008
41.
GongY, SasidharanN, LahejiF, et al.Microglial dysfunction as a key pathological change in adrenomyeloneuropathy. Ann Neurol, 2017; 82(5):813–827; doi: 10.1002/ana.25085
42.
EichlerFS, RenJQ, CossoyM, et al.Is microglial apoptosis an early pathogenic change in cerebral X-linked adrenoleukodystrophy? Ann Neurol, 2008; 63(6):729–742; doi: 10.1002/ana.21391
43.
BergnerCG, van der MeerF, WinklerA, et al.Microglia damage precedes major myelin breakdown in X-linked adrenoleukodystrophy and metachromatic leukodystrophy. Glia, 2019; 67(6):1196–1209; doi: 10.1002/glia.23598
44.
BenhamidaS, PflumioF, Dubart-KupperschmittA, et al.Transduced CD34+ cells from adrenoleukodystrophy patients with HIV-derived vector mediate long-term engraftment of NOD/SCID mice. Mol Ther, 2003; 7(3):317–324; doi: 10.1016/s1525-0016(03)00002-9
45.
van GeelBM, Poll-TheBT, VerripsA, et al.Hematopoietic cell transplantation does not prevent myelopathy in X-linked adrenoleukodystrophy: A retrospective study. J Inherit Metab Dis, 2015; 38(2):359–361; doi: 10.1007/s10545-014-9797-1
46.
GongY, MuD, PrabhakarS, et al.Adenoassociated virus serotype 9-mediated gene therapy for x-linked adrenoleukodystrophy. Mol Ther, 2015; 23(5):824–834; doi: 10.1038/mt.2015.6
47.
SobueG, Ueno-NatsukariI, OkamotoH, et al.Phenotypic heterogeneity of an adult form of adrenoleukodystrophy in monozygotic twins. Ann Neurol, 1994; 36(6):912–915; doi: 10.1002/ana.410360617
48.
KorenkeGC, FuchsS, KrasemannE, et al.Cerebral adrenoleukodystrophy (ALD) in only one of monozygotic twins with an identical ALD genotype. Ann Neurol, 1996; 40(2):254–257; doi: 10.1002/ana.410400221
49.
Di RoccoM, Doria-LambaL, CarusoU. Monozygotic twins with X-linked adrenoleukodystrophy and different phenotypes. Ann Neurol, 2001; 50(3):424; doi: 10.1002/ana.1220
50.
WandersRJA, BaesM, RibeiroD, et al.The physiological functions of human peroxisomes. Physiol Rev, 2023; 103(1):957–1024; doi: 10.1152/physrev.00051.2021
51.
FünfschillingU, SupplieLM, MahadD, et al.Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature, 2012; 485(7399):517–521; doi: 10.1038/nature11007
52.
LeeY, MorrisonBM, LiY, et al.Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature, 2012; 487(7408):443–448; doi: 10.1038/nature11314
BeyK, DeniaudJ, DubreilL, et al.Intra-CSF AAV9 and AAVrh10 administration in nonhuman primates: Promising routes and vectors for which neurological diseases? Mol Ther Methods Clin Dev, 2020; 17:771–784; doi: 10.1016/j.omtm.2020.04.001
55.
KuzminDA, ShutovaMV, JohnstonNR, et al.The clinical landscape for AAV gene therapies. Nat Rev Drug Discov, 2021; 20(3):173–174; doi: 10.1038/d41573-021-00017-7
56.
FlotteTR, GaoG. AAV Is now a medicine: We had better get this right. Hum Gene Ther, 2017; 28(4):307; doi: 10.1089/hum.2017.29041.trf
LingQ, HerstineJA, BradburyA, et al.AAV-based in vivo gene therapy for neurological disorders. Nat Rev Drug Discov, 2023; 22(10):789–806; doi: 10.1038/s41573-023-00766-7
GaoJ, GunasekarS, XiaZJ, et al.Gene therapy for CNS disorders: Modalities, delivery and translational challenges. Nat Rev Neurosci, 2024; 25(8):553–572; doi: 10.1038/s41583-024-00829-7
61.
van de BeekMC, DijkstraIM, van LentheH, et al.C26:0-Carnitine is a new biomarker for X-Linked adrenoleukodystrophy in mice and man. PLoS One, 2016; 11(4):e0154597; doi: 10.1371/journal.pone.0154597
62.
GalinoJ, RuizM, FourcadeS, et al.Oxidative damage compromises energy metabolism in the axonal degeneration mouse model of X-adrenoleukodystrophy. Antioxid Redox Signal, 2011; 15(8):2095–2107; doi: 10.1089/ars.2010.3877
63.
López-ErauskinJ, GalinoJ, RuizM, et al.Impaired mitochondrial oxidative phosphorylation in the peroxisomal disease X-linked adrenoleukodystrophy. Hum Mol Genet, 2013; 22(16):3296–3305; doi: 10.1093/hmg/ddt186
64.
RuizM, JovéM, SchlüterA, et al.Altered glycolipid and glycerophospholipid signaling drive inflammatory cascades in adrenomyeloneuropathy. Hum Mol Genet, 2015; 24(24):6861–6876; doi: 10.1093/hmg/ddv375
65.
JaspersYRJ, YskaHAF, BergnerCG, et al.Lipidomic biomarkers in plasma correlate with disease severity in adrenoleukodystrophy. Commun Med (Lond), 2024; 4(1):175; doi: 10.1038/s43856-024-00605-9
66.
KempS, PujolA, WaterhamHR, et al.ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: Role in diagnosis and clinical correlations. Hum Mutat, 2001; 18(6):499–515; doi: 10.1002/humu.1227
67.
OgakiK, KogaS, AokiN, et al.Adult-onset cerebello-brainstem dominant form of X-linked adrenoleukodystrophy presenting as multiple system atrophy: Case report and literature review. Neuropathology, 2016; 36(1):64–76; doi: 10.1111/neup.12230
68.
MansoorCA. Isolated Cerebellar Involvement in X-linked Adrenoleukodystrophy. Ann Indian Acad Neurol, 2020; 23(6):827–828; doi: 10.4103/aian.AIAN_48_20
69.
van GeelBM, KoelmanJH, BarthPG, et al.Peripheral nerve abnormalities in adrenomyeloneuropathy: A clinical and electrodiagnostic study. Neurology, 1996; 46(1):112–118; doi: 10.1212/wnl.46.1.112
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
